Simplify Logo

Full-Time

Scientist – Protein Biochemistry

Protein Folding/Misfolding

Confirmed live in the last 24 hours

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Biotechnology
Healthcare

Compensation Overview

$130k - $165kAnnually

+ Performance Bonus + Equity + Health Benefits

Mid, Senior

Palo Alto, CA, USA

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • D., MD, or Ph.D./MD degree and expertise in the field of **protein folding/misfolding** (e.g., biochemistry, biophysics, molecular biology, chemical biology, chemistry, structural biology). Prior industry experience or post-doctoral training is desirable but not required
  • Demonstrated record of achievement with at least one first-author publication in the field of protein folding/misfolding or chaperones is required
  • Experience and familiarity with techniques used for studying protein folding/misfolding, such as protein expression, purification, folding kinetics/pathway investigation, folding intermediate characterization, pulse proteolysis, protein thermal stability, urea denaturation, etc., is desirable
  • Experience with a wide range of biophysical (mass spectrometry (MS), surface plasmon resonance (SPR), microscale thermophoresis (MST), isothermal titration calorimetry (ITS), protein thermal shift (PTS), dynamic light scattering (DLS)) and plate-based biochemical (FRET, MSD, ELISA) techniques
  • Experience with multichannel pipettes and semi-automatic pipetting station is a plus
  • Experience with diseases related to protein folding/misfolding and pharmacological chaperones is a strong plus
  • Strong knowledge of chemistry concepts and structure biology, including an understanding of structure-activity relationships (SAR) and structure-based drug design.
Responsibilities
  • Use a variety of biochemical, biophysical, and pharmacological techniques to advance multiple small molecule drug candidates from discovery research to clinical development
  • Develop, optimize, troubleshoot, and execute novel biochemical and cellular assays to drive preclinical drug discovery
  • Interact with our medicinal chemists to support structural activity relationship learning
  • Drive basic research towards the clinic at hyperspeed
  • Independently design, execute, and analyze experiments within our top-notch laboratory
  • Communicate findings and implications to senior leadership

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company operates using a decentralized subsidiary model, where each subsidiary concentrates on creating therapies for particular diseases while sharing central resources. This structure enhances efficiency and allows for the simultaneous advancement of multiple drug programs. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Unlike many competitors, BridgeBio emphasizes independent thinking and transparency, enabling rapid, data-driven decision-making. The company's goal is to create significant therapeutic advancements by targeting diseases at their genetic source, ultimately bringing effective treatments to market more quickly.

Company Stage

IPO

Total Funding

$6.8B

Headquarters

Palo Alto, California

Founded

2014

Growth & Insights
Headcount

6 month growth

12%

1 year growth

45%

2 year growth

57%
Simplify Jobs

Simplify's Take

What believers are saying

  • Significant investments, such as the $46.84 million from Norges Bank and $200 million for the oncology spinout, indicate strong financial backing and growth potential.
  • The launch of BridgeBio Oncology Therapeutics with $200 million in funding highlights the company's commitment to advancing cancer treatments, particularly KRAS inhibitors.
  • Equity grants to new employees under the Amended and Restated 2019 Inducement Equity Plan demonstrate BridgeBio's commitment to attracting and retaining top talent.

What critics are saying

  • The competitive landscape in genetic disease therapies and oncology is intense, with numerous companies vying for market share.
  • The decentralized subsidiary model, while efficient, may lead to challenges in maintaining cohesive strategic direction and operational alignment.

What makes BridgeBio unique

  • BridgeBio's decentralized subsidiary model allows for focused and efficient drug development across multiple genetic diseases simultaneously, unlike traditional centralized biopharma companies.
  • The company's emphasis on genetic diseases with well-understood causes enables targeted and potentially more effective therapies, setting it apart from competitors with broader, less focused pipelines.
  • BridgeBio's robust pipeline of over 15 drug programs targeting 20 different genetic diseases showcases its diversified approach, reducing the traditional biopharma process timeline.